A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase Ib study.
Shigenori KadowakiToshiki MasuishiTakashi UraKeiji SugiyamaSeiichiro MitaniYukiya NaritaHiroya TaniguchiKei MuroPublished in: International journal of clinical oncology (2021)
The safety profile of the combination of cetuximab and FOLFOXIRI was acceptable and promising anti-tumor activity was demonstrated, supporting further study in patients with RAS wild-type mCRC.